Being an antibody development company that has ventured and prevailed into the CAR-T development space, ProMab holds several advantages over our competitors.
One unique advantage ProMab offers is that we have developed many different stable cell lines with tumor antigens to validate many bispecific antibodies. For example: Hela-CD19 cells, CHO-CD22, CHO-CS1, CHO-BCMA, CHO-CD37 , and others.
ProMab has also invested in cutting-edge technology with in-vitro assays utilizing XCelligenceTM System (ACEA/Agilent), as well as an in-house animal facility for in-vivo validation.
Case Study: Bispecific Antibodies
Figure 6. CEA-CD3 bispecific antibody detects CD3 in T cells. CEA-CD3 bispecific antibody specifically recognizes CEA in CEA-positive Lovo cells. CEA-CD3 bispecific antibody does not recognize in CEA-negative/low expression cell lines HCT116 and HT29.
CEA-CD3 RTCA (+)
Figure 7. CEA-CD3 kills CEA-positive Lovo cells. RTCA assay with Lovo cells and T cells.
CD19-CD3 RTCA (+)
Figure 8. CD19-CD3 bispecific antibody (Amgen) kills Hela-CD19 cells in a dose-dependent manner.
Figure 7. CEA-CD3 does not kills CEA-positive Lovo without T cells as shown in RTCA assay.